Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis.

Pang, B; Zhu, Y; Ni, J; Thompson, J; Malouf, D; Bucci, J; Graham, P; Li, Y

Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis.

Pang, B Zhu, Y

Ni, J Thompson, J Malouf, D Bucci, J Graham, P Li, Y

Permalink

Publisher:: IVYSPRING INT PUBL
Publication Type:: Journal Article
Citation:: Theranostics, 2020, 10, (5), pp. 2309-2326
Issue Date:: 2020-01-16

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.33 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Pang, B
dc.contributor.author	Zhu, Y https://orcid.org/0000-0002-8840-176X
dc.contributor.author	Ni, J
dc.contributor.author	Thompson, J
dc.contributor.author	Malouf, D
dc.contributor.author	Bucci, J
dc.contributor.author	Graham, P
dc.contributor.author	Li, Y
dc.date.accessioned	2021-01-03T22:36:10Z
dc.date.available	2019-10-01
dc.date.available	2021-01-03T22:36:10Z
dc.date.issued	2020-01-16
dc.identifier.citation	Theranostics, 2020, 10, (5), pp. 2309-2326
dc.identifier.issn	1838-7640
dc.identifier.issn	1838-7640
dc.identifier.uri	http://hdl.handle.net/10453/145049
dc.description.abstract	Prostate cancer (PCa) is a leading cause of cancer death for males in western countries. The current gold standard for PCa diagnosis - template needle biopsies - often does not convey a true representation of the molecular profile given sampling error and complex tumour heterogeneity. Presently available biomarker blood tests have limited accuracy. There is a growing demand for novel diagnostic approaches to reduce both the number of men with an abnormal PSA/ DRE who undergo invasive biopsy and the number of cores collected per biopsy. 'Liquid biopsy' is a minimally invasive biofluid-based approach that has the potential to provide information and improve the accuracy of diagnosis for patients' treatment selection, prognostic counselling and development of risk-adjusted follow-up protocols. Extracellular vesicles (EVs) are lipid bilayer-delimited particles released by tumour cells which may provide a real-time snapshot of the entire tumour in a non-invasive way. EVs can regulate physiological processes and mediate systemic dissemination of various types of cancers. Emerging evidence suggests that EVs have crucial roles in PCa development and metastasis. Most importantly, EVs are directly derived from their parent cells with their information. EVs contain components including proteins, mRNAs, DNA fragments, non-coding RNAs and lipids, and play a critical role in intercellular communication. Therefore, EVs hold promise for the discovery of liquid biopsy-based biomarkers for PCa diagnosis. Here, we review the current approaches for EV isolation and analysis, summarise the recent advances in EV protein biomarkers in PCa and focus on liquid biopsy-based EV biomarkers in PCa diagnosis for personalised medicine.
dc.format	Electronic-eCollection
dc.language	eng
dc.publisher	IVYSPRING INT PUBL
dc.relation.ispartof	Theranostics
dc.relation.isbasedon	10.7150/thno.39486
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	1112 Oncology and Carcinogenesis
dc.title	Extracellular vesicles: the next generation of biomarkers for liquid biopsy-based prostate cancer diagnosis.
dc.type	Journal Article
utslib.citation.volume	10
utslib.location.activity	Australia
utslib.for	1112 Oncology and Carcinogenesis
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
pubs.organisational-group	/University of Technology Sydney
utslib.copyright.status	open_access	*
dc.date.updated	2021-01-03T22:36:01Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	10
utslib.citation.issue	5

Abstract:

Prostate cancer (PCa) is a leading cause of cancer death for males in western countries. The current gold standard for PCa diagnosis - template needle biopsies - often does not convey a true representation of the molecular profile given sampling error and complex tumour heterogeneity. Presently available biomarker blood tests have limited accuracy. There is a growing demand for novel diagnostic approaches to reduce both the number of men with an abnormal PSA/ DRE who undergo invasive biopsy and the number of cores collected per biopsy. 'Liquid biopsy' is a minimally invasive biofluid-based approach that has the potential to provide information and improve the accuracy of diagnosis for patients' treatment selection, prognostic counselling and development of risk-adjusted follow-up protocols. Extracellular vesicles (EVs) are lipid bilayer-delimited particles released by tumour cells which may provide a real-time snapshot of the entire tumour in a non-invasive way. EVs can regulate physiological processes and mediate systemic dissemination of various types of cancers. Emerging evidence suggests that EVs have crucial roles in PCa development and metastasis. Most importantly, EVs are directly derived from their parent cells with their information. EVs contain components including proteins, mRNAs, DNA fragments, non-coding RNAs and lipids, and play a critical role in intercellular communication. Therefore, EVs hold promise for the discovery of liquid biopsy-based biomarkers for PCa diagnosis. Here, we review the current approaches for EV isolation and analysis, summarise the recent advances in EV protein biomarkers in PCa and focus on liquid biopsy-based EV biomarkers in PCa diagnosis for personalised medicine.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/145049